Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

from BioCentury This Week · host BioCentury

Acelyrin last week parlayed a late-stage asset for hidradenitis suppurativa and veteran leadership into one of biotech’s largest-ever NASDAQ IPOs. On the latest BioCentury This Week podcast, BioCentury’s editors discussed how Acelyrin generated outsized demand for its offering and assessed Alzheimer’s data for Eli Lilly's donanemab, the promise and challenges of digital endpoints and takeaways from the latest BioCentury Show, which featured incoming FogPharma CEO Mathai Mammen in conversation with Editor in Chief Simone Fishburn. This week’s podcast is sponsored by Cancer Research Horizons.Reach us by sending a text

Episode metadata supplied by the publisher feed · Published May 9, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

0:00 25:22

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioCentury This Week?

This episode is 25 minutes long.

When was this BioCentury This Week episode published?

This episode was published on May 9, 2023.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!